like pls_老虎社区_美港股上老虎

7f0c6b23
2021-07-06

like pls

Ocugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%

Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to

Ocugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":157250437,"tweetId":"157250437","gmtCreate":1625584711329,"gmtModify":1631889823797,"author":{"id":3571793226612481,"idStr":"3571793226612481","authorId":3571793226612481,"authorIdStr":"3571793226612481","name":"7f0c6b23","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>like pls</p></body></html>","htmlText":"<html><head></head><body><p>like pls</p></body></html>","text":"like pls","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/157250437","repostId":2149936563,"repostType":4,"repost":{"id":"2149936563","kind":"news","pubTimestamp":1625583201,"share":"https://ttm.financial/m/news/2149936563?lang=&edition=full","pubTime":"2021-07-06 22:53","market":"us","language":"en","title":"Ocugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2149936563","media":"Benzinga","summary":"Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to ","content":"<ul>\n <li>Armed with new data from its development partner&nbsp;<b>Bharat Biotech</b>,&nbsp;<b>Ocugen Inc</b>&nbsp;(NASDAQ: OCGN) plans to press ahead with plans to file for approval of their COVID-19 vaccine, Covaxin, in the U.S. and Canada.</li>\n <li>Covaxin has already been approved for restricted emergency use in India, getting the green light in January months before the final results from the trial were available.</li>\n <li>New data from the 25,800-patient Phase 3 trial show that the shot has an&nbsp;overall protective efficacy of 77.8%&nbsp;and 65.2% against the highly transmissible delta (B.1.617.2) variant.</li>\n <li>The two-dose vaccine based on an inactivated form of the virus formulated with an immune-boosting adjuvant showed to be 93.4% protective against severe symptomatic COVID-19.</li>\n <li>Adverse events reported were low, with 12.4% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events.</li>\n <li>Ocugen recently announced that it will pursue submission of a Biologics License Application (BLA) for its COVID-19 vaccine candidate in the U.S. and has initiated discussions with Health Canada for regulatory approval.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are up 14.3% at $8.33 during the premarket session on the last check Tuesday.</li>\n</ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ocugen-preps-us-filings-covid-112521982.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to press ahead with plans to file for approval of their COVID-19 vaccine, Covaxin, in the U.S. and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ocugen-preps-us-filings-covid-112521982.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGD":"New Gold","OCGN":"Ocugen"},"source_url":"https://finance.yahoo.com/news/ocugen-preps-us-filings-covid-112521982.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2149936563","content_text":"Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to press ahead with plans to file for approval of their COVID-19 vaccine, Covaxin, in the U.S. and Canada.\nCovaxin has already been approved for restricted emergency use in India, getting the green light in January months before the final results from the trial were available.\nNew data from the 25,800-patient Phase 3 trial show that the shot has an overall protective efficacy of 77.8% and 65.2% against the highly transmissible delta (B.1.617.2) variant.\nThe two-dose vaccine based on an inactivated form of the virus formulated with an immune-boosting adjuvant showed to be 93.4% protective against severe symptomatic COVID-19.\nAdverse events reported were low, with 12.4% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events.\nOcugen recently announced that it will pursue submission of a Biologics License Application (BLA) for its COVID-19 vaccine candidate in the U.S. and has initiated discussions with Health Canada for regulatory approval.\nPrice Action: OCGN shares are up 14.3% at $8.33 during the premarket session on the last check Tuesday.","news_type":1,"symbols_score_info":{"NGD":0.9,"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1544,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}

Ocugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%

评论（1）

热议股票